Kiberu S W, Pringle J H, Sobolewski S, Murphy P, Lauder I
Department of Pathology, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX.
Clin Mol Pathol. 1996 Oct;49(5):M268-72. doi: 10.1136/mp.49.5.m268.
Aim-To investigate whether clinical features of non-Hodgkin's lymphomas, at the time of first biopsy, correlate with studies of cell proliferation and cell death as well as with the level of bcl-2 expression.Methods-Bcl-2 expression, determined by immunocytochemistry, was compared with cell proliferation, measured using in situ hybridisation for histone mRNA, and cell death by apoptosis, measured using in situ end labelling for DNA cleavage.Results-Histone mRNA staining gave a labelling index of 30% of cells for reactive germinal centres, 5.2-13.5% of cells for low grade non-Hodgkin's lymphoma and 12.1-50.5% of cells for high grade non-Hodgkin's lymphoma. In situ end labelling gave a labelling index of 5.0-10.0% of cells for reactive germinal centres, 1.0-3.7% of cells for low grade non-Hodgkin's lymphoma and 4.7-13.5% of cells for high grade non-Hodgkin's lymphoma. There was a positive correlation between apoptotic index and proliferation index. More cases of low grade than high grade non-Hodgkin's lymphoma expressed bcl-2. There was no correlation between apoptotic index and bcl-2 expression for high grade non-Hodgkin's lymphoma.Conclusions-The molecular mechanisms controlling cell proliferation and death in non-Hodgkin's lymphoma are complex, probably involving a range of genes, including bcl-2. A better understanding of resistance to cell death is needed if the clinical goal of tailoring cancer treatment to individual tumours is to be achieved.
目的——研究非霍奇金淋巴瘤首次活检时的临床特征是否与细胞增殖、细胞死亡研究以及bcl-2表达水平相关。方法——通过免疫细胞化学测定的bcl-2表达与使用组蛋白mRNA原位杂交测量的细胞增殖以及使用DNA裂解原位末端标记测量的细胞凋亡死亡进行比较。结果——组蛋白mRNA染色显示，反应性生发中心细胞的标记指数为30%，低级别非霍奇金淋巴瘤细胞的标记指数为5.2%-13.5%，高级别非霍奇金淋巴瘤细胞的标记指数为12.1%-50.5%。原位末端标记显示，反应性生发中心细胞的标记指数为5.0%-10.0%，低级别非霍奇金淋巴瘤细胞的标记指数为1.0%-3.7%，高级别非霍奇金淋巴瘤细胞的标记指数为4.7%-13.5%。凋亡指数与增殖指数之间存在正相关。低级别非霍奇金淋巴瘤表达bcl-2的病例多于高级别非霍奇金淋巴瘤。高级别非霍奇金淋巴瘤的凋亡指数与bcl-2表达之间无相关性。结论——控制非霍奇金淋巴瘤细胞增殖和死亡的分子机制很复杂，可能涉及一系列基因，包括bcl-2。如果要实现针对个体肿瘤定制癌症治疗的临床目标，就需要更好地了解对细胞死亡的抗性。
